Research programme: CC-chemokine receptor 3 antagonists - Millennium/Roche Bioscience

Drug Profile

Research programme: CC-chemokine receptor 3 antagonists - Millennium/Roche Bioscience

Alternative Names: CCR3 antagonists research programme - Millennium/Roche Bioscience

Latest Information Update: 23 Aug 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Millennium Pharmaceuticals; Roche Palo Alto LLC
  • Class
  • Mechanism of Action CCR3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Asthma; Hypersensitivity

Most Recent Events

  • 26 Jan 2000 LeukoSite has been merged into Millennium Pharmaceuticals
  • 05 Jun 1998 New profile
  • 05 Jun 1998 Preclinical development for Allergy in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top